Treatment for Sapho Syndrome: A Multimodality Therapy

Adalimumab treatment for SAPHO syndrome.

© 2010 The Authors. doi: 10.2340/00015555-0822 Journal Compilation © 2010 Acta Dermato-Venereologica. ISSN 0001-5555 SAPHO syndrome is a rare condition of unknown pathogenesis originally described by Chamot et al. (1) in 1987. Onset usually occurs in young adults, with no differences between sexes and it is manifested by synovitis, acne, pustulosis, hyperostosis and osteitis. Of paramount impor...

SAPHO syndrome: a review

INTRODUCTION Synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) is an acronym for various osteoarticular and dermatological manifestations that can appear in the same patient. It is a rare syndrome, but since its awareness has increased, there have been more and more such reports in the literature. AIMS The objectives of this review are to summarize the current state of knowledge on pedi...

SAPHO Syndrome

SAPHO Syndrome

In 1987, Chamot et al attempted to unify the various descriptions of osteoarticular disease associated with skin manifestations into a syndrome with the acronym SAPHO: synovitis, acne, pustulosis, hyperostosis, and osteitis (Chamot et al., 1987). Furthermore, the clinical feature of aseptic chronic recurrent multiple osteomyelitis (CRMO) accompanied by pustulosis with its typical presentation i...

Treatment approaches for interstitial cystitis: multimodality therapy.

Interstitial cystitis is an increasingly common disease characterized by urgency, frequency, and pelvic pain. Its etiology is poorly understood but is likely to be multifactorial. A proposed pathophysiology describing a cascade of events, including epithelial dysfunction, mast cell activation, and neurogenic inflammation, is presented. Using this model, multimodality therapy regimens have been ...